HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Zacks Rank    Equity Research    Premium Home    My Account    Help    

Profit from the Pros – Zacks Free Email Newsletter
Our free email newsletter is filled with timely stock picks and market commentary. Sign up for free. Already on board? Check out the archive.
Quote:
Login Free Membership
Search:

 
Analyst Blog  

BioMarin a Buy with a $28 Target

January 06, 2009 | Comments: 0
Recommended this article (1)
Print    Share

BioMarin Pharmaceutical Inc. (BMRN - Analyst Report) develops enzyme therapies for serious chronic genetic disorders and other diseases. Its leading product, Aldurazyme, is used for treating the ultra-rare genetic disorder
mucopolysaccharidosis-I (MPS-I) while its second product, Naglazyme, is appoved for the treatment of MPS-VI.

Recently, the company received both FDA and EC approval for its third product, Kuvan, for the treatment of PKU. Strong product sales will drive the company to profitability in 2008 and beyond.

The company's clinical pipeline, too, remains impressive. As such, we maintain our Buy rating on the stock with a price target of $28.

Read the full analyst report on BMRN


Email

Print

Share

RSS

Rate Pos

Rate Neg

Comment
Read/Post Comments (0) | Recommended this article (1)
 Posting Comment...
There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]
Comments (Limit 1000 Characters - Used: 0)
Display Name: Email Address:  
 Loading Comments...
Be the first to comment on this article!

More Zacks Resources

Market Summary Nov 08, 2009 12:41 pm ET
DJIA 10023.42  17.46 0.17%
NASD 2112.44  7.12 0.34%
S&P 500 1069.3  2.67 0.25%
Sponsored Links